Cephalon Inc. 's acquisition of US rights to Alkermes Inc. 's Vivitrex (long-acting formulation of the alcohol abuse drug naltrexone) is a clear sign that mid-sized companies with marketed products can—thanks to their significant cash flows—contend with Big Pharma for important specialist products [See Deal].
Not only did Cephalon convince Alkermes it could do as good or better a job marketing the product than a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?